PRISM BioLab Co.,LTD

206A

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-14FY2026 Q3

Revenue

7.4100M JPY

YoY +84.2%

Operating Income

-8.3100M JPY

YoY -10.1%

Net Income

-8.8100M JPY

YoY +31.8%

EPS

-22.9JPY

YoY -3.8%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

6.8億円

2.5億円

-1.9億円

-6.2億円

-10.5億円

Rev: 3.1億円Op: -7.8億円NI: -10.5億円

Rev: 6.8億円Op: -7.7億円NI: -8.3億円

2024/FY2025/FY

Full-Year Progress

FY2026 Q3

Net Income-

Revenue Progress3.700M

Revenue Forecast-

Net Income Progress-

Net Income Forecast-

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan